Farydak Approval History
Farydak (panobinostat) is a histone deacetylase inhibitor for the combination treatment of multiple myeloma.
Development History and FDA Approval Process for Farydak
|Feb 23, 2015||FDA Approves Farydak (panobinostat) for Multiple Myeloma|
|Nov 6, 2014||Novartis Announces Outcome of FDA Advisory Committee Meeting for LBH589 (Panobinostat)|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.